Supplemental Material 1. Distribution of payment values per gastroenterologist

- **2016**
- **2017**
- **2018**
- **2019**
Supplemental Material 2. Payment concentration

2016

Cumulative percentage of total payments (%) vs. Percentage of gastroenterologists (%)

2017

Cumulative percentage of total payments (%) vs. Percentage of gastroenterologists (%)

2018

Cumulative percentage of total payments (%) vs. Percentage of gastroenterologists (%)

2019

Cumulative percentage of total payments (%) vs. Percentage of gastroenterologists (%)
Supplemental Material 3. Payments to board members and clinical practice guideline authors with the board certification as gastroenterologists

262 authors of 10 JSG clinical practice guidelines between 2016 and 2021

31 (11.8%) authors without JSG board certification as gastroenterologist

231 (88.2%) authors with JSG board certification as gastroenterologist

209 (90.5%) authors received personal payments from pharmaceutical companies between 2016 and 2019.

Chairperson authors: $106,069 in median (IQR: $25,556-$289,914)
Non-chairpersons authors: $11,131 in median (IQR: $1,801-$61,293)

24 board members as of January 2022

24 (100%) board members with the JSG board certification as gastroenterologist

24 (100%) board members received a median of $132,777 (IQR: 79,771-$215,036) in personal payments
Supplemental Material 4. Payment categories by company

- Takeda Pharmaceutical
- AbbVie
- Otsuka Pharmaceutical
- Daiichi Sankyo
- Mitsubishi Tanabe Pharma
- Taiho Pharmaceutical
- MSD
- EA Pharma
- Chugai Pharmaceutical
- AstraZeneca

Proportion (%)

- Lecturing
- Consulting
- Writing
- Other